高营销低增长
Search documents
暴跌900%!常年找顶流代言,知名企业巨亏!实控人被立案
Nan Fang Du Shi Bao· 2026-01-30 16:20
Core Viewpoint - The company Beiqing Song (688793.SH), known as the "first stock of smart health hardware," has reported a significant turnaround in its 2025 annual performance forecast, shifting from a slight profit in 2024 to a substantial loss, with a year-on-year decline exceeding 900% [1][2]. Financial Performance - For 2025, the company expects a net profit loss attributable to shareholders of between 84 million and 105 million yuan, with a non-recurring net profit loss of between 71 million and 92 million yuan [2]. - In 2024, the company achieved a net profit of 10.25 million yuan, indicating a drastic decline in performance within a year [2]. - The company's revenue for the first three quarters of 2025 was approximately 552 million yuan, a significant decrease of 34.07% year-on-year, with a net profit loss of 65.63 million yuan, a year-on-year decline of 600.98% [6]. Marketing and Operational Challenges - The company's high marketing expenses, which accounted for nearly 60% of revenue, have not effectively driven revenue growth, leading to a significant squeeze on profit margins [7][9]. - In the first three quarters of 2025, the company spent approximately 316 million yuan on sales expenses, a reduction of 27.52% year-on-year, but this decrease was insufficient compared to the 34.07% drop in revenue [7]. - The proportion of sales expenses to revenue was 57.32% in the first three quarters of 2025, indicating that for every 100 yuan of revenue, nearly 60 yuan was spent on sales [7]. Management and Regulatory Issues - The actual controller of the company, Ma Xuejun, is under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure laws [10]. - There have been long-standing issues with fund occupation by Ma Xuejun, with a total of 12.08 million yuan occupied through various means, raising concerns about internal controls [12]. - The company has faced multiple regulatory inquiries and has received several regulatory letters due to these internal control issues and information disclosure inaccuracies [13].